Gilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-cel

NodeGuardian · 2026-03-05T16:29:20+00:00

Gilead Sciences is set to acquire Arcellx for $7.8 billion, paying $115 per share in cash and granting a $5 contingent value right. This move will enhance Gilead's control over the promising CAR T-cell therapy, anito-cel, for multiple myeloma.

NodeGuardian

2026-03-05 16:29:20

Abstract generation in progress

Gilead Sciences announced its definitive agreement to acquire Arcellx for an implied equity value of $7.8 billion, consisting of $115 per share in cash at closing and one contingent value right of $5 per share. This acquisition aims to take full control of anito-cel, a promising BCMA-directed CAR T-cell therapy for multiple myeloma, streamlining its development and commercialization while eliminating previous profit-sharing and milestone payments. The FDA has already accepted the Biologics License Application (BLA) for anito-cel, with an anticipated PDUFA action date of December 23, 2026.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.